TY - JOUR

T1 - The genomics of heart failure

T2 - design and rationale of the HERMES consortium

AU - Lumbers, R Thomas

AU - Shah, Sonia

AU - Lin, Honghuang

AU - Czuba, Tomasz

AU - Henry, Albert

AU - Swerdlow, Daniel I

AU - Mälarstig, Anders

AU - Andersson, Charlotte

AU - Verweij, Niek

AU - Holmes, Michael V

AU - Ärnlöv, Johan

AU - Svensson, Per

AU - Hemingway, Harry

AU - Sallah, Neneh

AU - Almgren, Peter

AU - Aragam, Krishna G.

AU - Asselin, Geraldine

AU - Backman, Joshua D.

AU - Biggs, Mary L

AU - Bloom, Heather L.

AU - Boersma, Eric

AU - Brandimarto, Jeffrey

AU - Brown, Michael R.

AU - Brunner-La Rocca, Hans-Peter

AU - Carey, David J

AU - Chaffin, Mark D.

AU - Chasman, Daniel I.

AU - Chazara, Olympe

AU - Chen, Xing

AU - Chen, Xu

AU - Chung, Jonathan H.

AU - Chutkow, William

AU - Cleland, John G F

AU - Cook, James P

AU - de Denus, Simon

AU - Dehghan, Abbas

AU - Delgado, Graciela E

AU - Denaxas, Spiros

AU - Doney, Alexander S.

AU - Dörr, Marcus

AU - Dudley, Samuel C.

AU - Engström, Gunnar

AU - Esko, Tõnu

AU - Fatemifar, Ghazaleh

AU - Felix, Stephan B

AU - Finan, Chris

AU - Køber, Lars

AU - Stender, Steen

AU - Regeneron Genetics Center

N1 - Publisher Copyright: © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

PY - 2021

Y1 - 2021

N2 - Aims: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34–90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01–0.05) at P < 5 × 10−8 under an additive genetic model. Conclusions: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.

AB - Aims: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34–90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01–0.05) at P < 5 × 10−8 under an additive genetic model. Conclusions: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.

U2 - 10.1002/ehf2.13517

DO - 10.1002/ehf2.13517

M3 - Journal article

C2 - 34480422

AN - SCOPUS:85114632006

VL - 8

SP - 5531

EP - 5541

JO - E S C Heart Failure

JF - E S C Heart Failure

SN - 2055-5822

IS - 6

ER -